Drug target Mendelian randomization studies have demonstrated prospective evidence that the triglyceride-lowering alleles in the LPL pathway, which controls triglyceride hydrolysis, may be causally associated with lower risks of coronary heart disease and type 2 diabetes independent of LDL-C26,27. Here, LPL is linked to coronary artery disorder.